Ohio, Cardinal Health invest $10M for PET imaging

The Ohio State University (OSU), Cardinal Health and Ohio Third Frontier are investing more than $10 million in molecular imaging research by combining Ohio State’s Wright Center of Innovation in Biomedical Imaging research capabilities and Cardinal Health’s manufacturing and commercialization expertise for molecular imaging agents.

The partnership will expand the molecular imaging research program at OSU’s Wright Center of Innovation in Biomedical Imaging to include a new Molecular Imaging Technology Center. The center will house OSU’s researchers, as well as Cardinal’s radiopharmaceutical manufacturing facility and nuclear pharmacy operations. In addition, a distinguished faculty position in radiopharmaceutical chemistry--along with other researchers--will be added to OSU’s department of radiology.

“While we expect to immediately create up to a dozen highly-skilled jobs with this exciting new partnership, the true value is collaborating with Ohio State and Cardinal Health to attract the best and brightest researchers to Ohio and continue to diversify our state’s economy,” said Ohio Lieutenant Governor Lee Fisher. “The new center is expected to bring additional investment from the pharmaceutical industry, which can leverage the research and commercialization expertise offered by this partnership for new radiopharmaceutical development projects.”

As new agents move through the development pipeline, Cardinal said it will also support manufacturing and dispensing for clinical trials across its national network of radiopharmaceutical facilities.


Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.